Last reviewed · How we verify
Rezafungin for Injection
Rezafungin is an echinocandin antifungal that inhibits fungal cell wall synthesis by targeting 1,3-beta-D-glucan synthase.
Rezafungin is an echinocandin antifungal that inhibits fungal cell wall synthesis by targeting 1,3-beta-D-glucan synthase. Used for Invasive candidiasis, Candidemia.
At a glance
| Generic name | Rezafungin for Injection |
|---|---|
| Also known as | Intravenous antifungal therapy |
| Sponsor | Mundipharma Research Limited |
| Drug class | Echinocandin antifungal |
| Target | 1,3-beta-D-glucan synthase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Rezafungin binds to and inhibits the fungal enzyme 1,3-beta-D-glucan synthase, which is essential for the synthesis of beta-glucan, a critical structural component of the fungal cell wall. This disruption of cell wall integrity leads to fungal cell lysis and death. As an echinocandin, it has broad-spectrum activity against Candida and Aspergillus species with a long half-life suitable for intravenous administration.
Approved indications
- Invasive candidiasis
- Candidemia
Common side effects
- Infusion-related reactions
- Elevated liver enzymes
- Hypokalemia
- Headache
Key clinical trials
- Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (PHASE3)
- Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options (PHASE2)
- Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis (PHASE3)
- Safety and Pharmacokinetics of Rezafungin (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |